COMPASS Pathways plc

CMPS
$14.82 (+ $1.24 + 9.13%)
Last updated: 2026-06-27 14:59 UTC
CMPS Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealthcare
IndustryMedical Care Facilities
ISINUS20451W1018
CUSIP20451W101
Market Price14.82
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-2.72
Market Cap$671.2M
Book Value0.39
Price to Book17.832
Beta1.94
52w High7.15
52w Low2.25
Next Earnings DateN/A

COMPASS Pathways plc trades under ticker CMPS on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US20451W1018, CUSIP 20451W101.

About the Company
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Price History